PATENT
ATTORNEY DOCKET NUMBER: 50125/095001

Certificate of Mailing

Date of Deposit: September 2, 2004 Label Number: EV293693801US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as **"Express Mail Post Office to Addressee"** with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De La Cruz
Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Jörg Stürzebecher et al.	Art Unit:	
Serial No.:	Not yet assigned	Examiner:	
Filed:	September 2, 2004	Customer No.:	21559
Title:	INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME		

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed with the application.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 2 September 2004

Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

F:\50125\50125.095001 Information Disclosure Statement filed with app.doc

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/095001
	Serial No.	Not yet assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Jörg Stürzebecher et al.
	Filing Date	September 2, 2004
	Group	Not yet assigned
(37 C.F.R. § 1.98(b))	IDS Filed	September 2, 2004

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	6,030,972	02/29/00	Bohm et al.			
	5,726,159	03/10/98	Schacht et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 01/96366 A2	12/20/01	PCT			
	WO 00/58346	10/05/00	PCT			
	WO 94/29336	12/22/94	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Dixon, "The Determination of Enzyme Inhibitor Constants," *Biochem. J.* 55:170-171 (1953).
	Frèrot et al., "PyBOP® and PyBroP: Two Reagents for the Difficult Coupling of the α, α-Dialkyl Amino Acid, Aib," *Tetrahedron* 47:259-270 (1991).
	Hara et al., "DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa," *Thrombosis and Haemostasis* 71:314-319 (1994).
	Herbert et al., "DX 9065A, a Novel, Synthetic, Selective and Orally Active Inhibitor of Factor Xa: *In Vitro* and *In Vivo* Studies," *The Journal of Pharmacology and Experimental Therapeutics* 276:1030-1038 (1996).
	Ho et al., "Exploratory Solid-Phase Synthesis of Factor Xa Inhibitors: Discovery and Application of P_3-Heterocyclic Amides as Novel Types of Non-Basic Arginine Surrogates," *Bioorganic & Medicinal Chemistry Letters* 9:3459-3464 (1999).
	Kettner et al., "The Selective Affinity Labeling of Factor Xa by Peptides of Arginine Chloromethyl Ketone," *Thrombosis Research* 22:645-652 (1981).
	Kim et al., "Preparation of Argatroban Analog Thrombin Inhibitors with Reduced Basic Guanidine Moiety, and Studies of Their Cell Permeability and Antithrombotic Activities," *Med. Chem. Res.* 377-383 (1996).
	Kirk, "4-Lithio-1-Tritylimidazole as a Synthetic Intermediate, Synthesis of Imidazole-4-Carboxaldehyde," *J. Heterocyclic Chem* 22:57-59 (1985).
	Künzel et al., "4-Amidinobenzylamine-Based Inhibitors of Urokinase," *Bioorganic & Medicinal Chemistry Letters* 12:645-648 (2002).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/006001
	Serial No.	10/506383 Not yet assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Jörg Stürzebecher et al.
	Filing Date	September 2, 2004
	Group	Not yet assigned
(37 C.F.R. § 1.98(b))	IDS Filed	September 2, 2004

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Lee et al., "Noncovalent Thrombin Inhibitors Incorporating an Imidazolylethynyl P1," Bioorganic & Medicinal Chemistry Letters 10:2775-2778 (2000).
	Maduskuie et al., "Rational Design and Synthesis of Novel, Potents Bis-Phenylamidine Carboxylate Factor Xa Inhibitors," *J. Med. Chem.* 41:53-62 (1998).
	Mohan et al., "Solid-Phase Synthesis of N-Substituted Amidinophenoxy Pyridines as Factor Xa Inhibitors," *Bioorganic & Medicinal Chemistry Letters* 8:1877-1882 (1998).
	Phillips et al., "Discovery of N-[2-[5-[Amino (imino)Methyl]-2-Hydroxyphenoxy] -3,5-Difluoro-6-[3-(4,5-Dihydro-1-Methyl-1 H-Imidazol-2-yl) Phenoxy] Pyridin-4-yl]-N-methylglycine (ZK-807834): A Potent, Selective, and Orally Active Inhibitor of the Blood Coagulation Enzyme Factor Xa[1]," *J. Med. Chem.* 41:3557-3562 (1998).
	Ostrem et al., "Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors Via Combinatorial Chemistry," *Biochemistry* 37:1053-1059 (1998).
	Quan et al., "Bisbenzamidine Isoxazoline Derivatives as Factor Xa Inhibitors," *Bioorganic & Medicinal Chemistry Letters* 7:2813-2818 (1997).
	Sato et al., "Antithrombotic Effects of YM-60828, a Newly Synthesized Factor Xa Inhibitor, in Rat Thrombosis Models and its Effects on Bleeding Time," *British Journal of Pharmacology* 123:92-96 (1998).
	Sato et al., "YM-60828, a Novel Factor Xa Inhibitor: Separation of its Antithrombotic Effects From its Prolongation of Bleeding Time," *European Journal of Pharmacology* 339:141-146 (1997).
	Schechter et al., "On the Size of the Active Site in Proteases," *Biochemical and Biophysical Research Communications*," 27:157-162 (1967).
	Soll et al., "Amidinohydrazones as Guanidine Bioisosteres: Application to a New Class of Potent, Selective and Orally Bioavailable, Non-Amide-Based Small Molecule Thrombin Inhibitors," *Bioorganic & Medicinal Chemistry Letters* 10:1-4 (2000).
	Sperl et al., "Urethanyl-3-Amidinophenylalanine Derivatives as Inhibitors of Factor Xa. X-Ray Crystal Structure of a Trypsin/Inhibitor Complex and Modeling Studies," *Biol. Chem.* 381:321-329 (2000).
	Stürzebecher et al., "Synthetic Inhibitors of Bovine Factor Xa and Thrombin Comparison of Their Anticoagulant Efficiency," *Thrombosis Research* 54:245-252 (1989).
	Sucker et al., "Pharm. Techn. 2.," Bauer, Georg Thieme Verlag, Stuttgart, 1991.
	Von der Saal et al, "Derivatives of 4-Amino-Pyridine as Selective Thrombin Inhibitors," *Bioorganic & Medicinal Chemistry Letters* 7:1283-1288 (1997).
	Zhu et al., "Recent Advances in Inhibitors of Factor Xa in the Prothrombinase Complex," *Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drugs* 1:63-88 (1999).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.